Inhibition of RhoA or Rac1? Mechanism of cholesterol- independent beneficial effects of statins

Circulation Journal

Volumn 73, Issue 2, 2009, Pages 231-232

  Rikitake, Yoshiyuki ^a,b   Hirata, Ken Ichi ^a,b  

^a Division of Cardiovascular Medicine   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATROVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PITAVASTATIN; PRAVASTATIN; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DRUG PROTEIN BINDING; EDITORIAL; ENDOTHELIUM CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RAC1 GTP-BINDING PROTEIN; RATS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN;

EID: 59449100515     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-1078     Document Type: Editorial

References (9)

1. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
2. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
3. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361 - 370.
4. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol 2008; 9: 690 - 701.
5. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: A decade of hypertrophic signaling hits. Circ Res 2006; 98: 730-742.
6. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005; 183: 1-16.
7. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
8. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
9. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767 - 1775.